Related Experiment Videos
Corticosteroids and surfactant for prevention of neonatal RDS
1Research Unit for Experimental Perinatal Pathology, St. Göran's Hospital, Stockholm, Sweden.
Insights
Antenatal corticosteroids and surfactant therapy can prevent respiratory distress syndrome (RDS) in preterm infants. Combining antenatal corticosteroids with thyrotrophin-releasing hormone (TRH) shows promising synergistic effects for RDS prevention.
Area of Science:
- Neonatal medicine
- Pulmonology
- Endocrinology
Background:
- Neonatal respiratory distress syndrome (RDS) is a significant risk for preterm infants.
- Two primary prevention strategies exist: antenatal hormone therapy and postnatal surfactant treatment.
Purpose of the Study:
- To evaluate the efficacy of antenatal corticosteroids and surfactant therapy for preventing RDS.
- To explore synergistic effects of combined antenatal and postnatal treatments, including thyrotrophin-releasing hormone (TRH).
Main Methods:
- Review of large randomized clinical trials on antenatal corticosteroids and prophylactic surfactant.
- Analysis of animal experiments and recent clinical trials investigating combined therapies.
Main Results:
- Antenatal corticosteroids accelerate fetal lung maturation and reduce RDS risk.
- Prophylactic surfactant offers limited additional benefit in infants pretreated with corticosteroids.
- Antenatal corticosteroids and postnatal surfactant show synergistic effects in animal models.
- Combined antenatal corticosteroids and TRH demonstrate promising results in clinical trials.
Conclusions:
- Antenatal corticosteroids are effective in lung maturation and RDS prevention.
- Combination therapy with antenatal corticosteroids, TRH, and postnatal surfactant may offer enhanced benefits for neonatal lung function.
Abstract:
Two main strategies are available for the prevention of neonatal respiratory distress syndrome (RDS) in cases of preterm delivery: antenatal administration of hormones that accelerate fetal lung maturation, and prophylactic treatment with surfactant soon after birth. The efficacy of each of these therapeutic regimens has been well documented in large randomized clinical trials, and recent data furthermore indicate that, in preterm babies with lowered risk of RDS after antenatal corticosteroid treatment, the odds for developing RDS are not further reduced by prophylactic treatment with surfactant. Corticosteroids and surfactant operate by clearly different mechanisms. The steroids stimulate (via the fibroblast-pneumonocyte factor) production of surfactant phospholipids by alveolar type II cells, enhance the expression of surfactant-associated proteins, reduce microvascular permeability, and accelerate overall structural maturation of the lungs. However, the increment in pool size of surfactant resulting from antenatal treatment with corticosteroids is trivial relative to the dose of exogenous surfactant required for successful prophylaxis at birth. Data from animal experiments indicate that antenatal corticosteroids and postnatal surfactant treatment have synergistic beneficial effects on neonatal lung function, and that these effects can be further potentiated by adding antenatal administration of thyrotrophin releasing hormone (TRH). Promising results have been obtained in recent clinical trials combining antenatal treatment with corticosteroids and TRH for prevention of RDS.